# SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma

> **NCT00002548** · PHASE3 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 899 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** carmustine
- **DRUG:** cyclophosphamide
- **DRUG:** dexamethasone
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** melphalan
- **DRUG:** prednisone
- **DRUG:** vincristine sulfate
- **PROCEDURE:** allogeneic bone marrow transplantation
- **PROCEDURE:** autologous bone marrow transplantation
- **PROCEDURE:** peripheral blood stem cell transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002548
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1994-01
- **Primary completion:** 2003-10
- **Final completion:** 2006-11
- **Target enrollment:** 899 (ACTUAL)
- **Last updated:** 2015-03-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002548, "SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00002548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*